Cara Therapeutics, Inc. is an emerging biopharmaceutical company with an initial commercial presence, dedicated to the development and commercialization of novel pharmaceutical compounds. Its core mission revolves around addressing pruritus (itching) and pain, primarily by selectively modulating kappa opioid receptors, with a particular focus on the United States. The company's therapeutic pipeline features agents designed to interact with the body's peripheral nervous system and immune cells.